Saudi Gazette report
RIYADH — The Saudi Meals and Drug Authority (SFDA) has suspended the registration of a European pharmaceutical manufacturing unit following the invention of significant violations of Good Manufacturing Practices (GMP) throughout an exterior inspection.
The choice got here after SFDA inspectors recognized elementary lapses within the manufacturing unit’s manufacturing procedures and inside high quality techniques, posing a direct threat to the security of pharmaceutical merchandise supposed for export to Saudi Arabia.
The suspension was enacted as a precautionary measure to stop the distribution of probably unsafe medicines within the Kingdom.
The inspection, carried out below the SFDA’s international manufacturing unit oversight program, aligns with worldwide regulatory requirements and concerned a complete overview of the power’s manufacturing operations, qc, and distribution protocols.
A number of European regulatory companies have since reached out to the SFDA to look at its technical findings and take additional actions, reflecting rising worldwide recognition of the SFDA’s regulatory rigor and world function in pharmaceutical security.
The Authority pressured that the monitoring of abroad manufacturing websites is a key pillar of its regulatory framework and is carried out independently utilizing scientific and technical information.
It reaffirmed its dedication to shopper security and pledged to proceed taking decisive motion towards any producer discovered to be in violation of security protocols.